Fulcrum Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $80,000 | $0 | $871 |
Gross Profit | 62,739 | -479 | 363 | |
EBITDA | -22,694 | 55,809 | -29,355 | -27,484 |
EBIT | -23,063 | 52,492 | -29,834 | -27,992 |
Net Income | -21,696 | 55,409 | -26,870 | -24,756 |
Net Change In Cash | 0 | 80,000 | 0 | 871 |
Free Cash Flow | -19,091 | 58,899 | -25,312 | -23,235 |
Cash | 72,630 | 86,702 | 39,949 | 25,563 |
Basic Shares | 62,409 | 63,587 | 61,984 | 61,871 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $2,805 | $6,342 | $19,163 | $8,823 |
Gross Profit | 2,805 | 3,928 | 19,163 | 8,823 |
EBITDA | -108,492 | -109,720 | -78,539 | -69,232 |
EBIT | -110,664 | -112,134 | -81,054 | -71,611 |
Net Income | -97,335 | -105,621 | -78,332 | -68,440 |
Net Change In Cash | 2,805 | 6,342 | 19,163 | 8,823 |
Cost of Revenue | -314 | -21,640 | -39,661 | |
Free Cash Flow | -91,473 | -99,013 | -80,191 | -54,997 |
Cash | 25,563 | 35,098 | 35,412 | 57,052 |
Basic Shares | 61,310 | 44,991 | 35,361 | 25,354 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.46 |
2024-06-30 | $0.87 |
2024-03-31 | -$0.43 |
2023-12-31 | -$0.40 |
